Together Ventures invests in Cori Clinical
Funding Provisional 86% confidence first seen
Tech.eu reports that Cori Clinical raised a $4 million seed round led by Breega, with participation from Together Ventures (along with other investors). The funding supports Cori’s AI platform for clinical trial design, aiming to consolidate prior trial knowledge with regulatory and registry information to reduce protocol errors and cut clinical trial set-up costs and delays. This matters because it highlights Together Ventures backing a tool targeted at accelerating and improving the regulatory-heavy process of clinical trial planning.
The deal
Cori Clinical $4M Seed · announced 7 Oct 2026
Investors Breega Enzo Heartfelt Together Ventures Bynd
Deal terms as reported in the coverage below.
Decision brief
- What changed
- Cori Clinical raised a $4 million seed round led by Breega, with participation from Together Ventures and other investors, to fund its AI platform for clinical trial design. According to the coverage, the company will use the capital to expand delivery capacity, grow its team, and deepen its regulatory and clinical intelligence.
- Why it matters
- For leaders in pharma, biotech, and clinical operations, this financing signals investor support for AI tools aimed at reducing trial protocol errors and lowering study set-up costs in a highly regulated workflow. If Cori’s platform performs as described, it could affect how organizations resource trial planning, vendor selection, and protocol development, especially where delays or rework materially increase program cost and time.
- Evidence
- The information comes from a single Tech.eu report stating that Cori Clinical raised $4 million in seed funding led by Breega, with Together Ventures participating. The article says Cori’s platform combines prior trial knowledge with regulatory and registry information, and attributes performance claims such as at least 33% lower average trial set-up costs and 82% of protocol errors being avoidable to the company’s own estimates and internal AI review.
- What remains uncertain
- The reported cost-reduction and error-avoidance figures are company-provided and not independently validated in the coverage. It is also unclear from the article which customer segments, trial phases, or therapeutic areas have adopted the platform, and how broadly its results generalize across sponsors and regulators.
- Monitor next
- Watch for named customer deployments, independent validation of protocol quality or cost savings, and any disclosed integrations into sponsor or CRO trial-design workflows.
Analytical support, not advice — assumptions and open questions stated above.